NCT02100150View on ClinicalTrials.gov

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

PHASE2TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Concussion
Interventions
DRUG

NNZ-2566

Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.

DRUG

Placebo

Strawberry flavored solution 0.5% v/v in Water for Injection

Trial Locations (1)

28307

Fort Bragg, Fayetteville

Sponsors
All Listed Sponsors
lead

Neuren Pharmaceuticals Limited

INDUSTRY

NCT02100150 - A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI) | Biotech Hunter | Biotech Hunter